Nearly 50% of oral cavity squamous cell carcinomas (OSCC) contain missense mutations in the p53 gene, making mutant p53 sequence peptides attractive candidates for cellular immunotherapy. The probability is greater, however, that tumors will present wild-type sequence peptides derived from mutant p53 molecules rather that mutant sequence peptides. Targeting wild- type sequence p53 does raise the possibility that such immunotherapy might induce an autoimmune response capable of responding to normal tissues, as well as an antitumor response. In a preclinical studies, however, a vaccine consisting of a wild-type sequence p53 peptide pulsed onto dendritic cells (DC) was shown in mice to be effective in inducing anti- tumor CTL which were not reactive against normal cells, and tumor rejection in the immunization and therapy settings. Recently, two human wild-type sequence peptides, p53 149-157 and p53 264-272, were identified as being naturally presented by tumors using anti-peptide CTL generated in HLA-A2.1-transgenic mice. To guide the clinical development of p53 peptide-based immunotherapy, we propose to generate anti-tumor CTL capable of recognizing these naturally presented epitopes by culturing peripheral blood lymphocytes (PBL) from HLA-A2.1+ individuals with autologous DC pulsed with the p53 peptides. We also propose that DC cultured with wild- type p53 protein will permit identification of additional T-cell-defined p53 epitopes presented by HLA-A2 and other class I HLA molecules, as well as class II molecules, thereby broadening the applicability of p53-based immunotherapy. Following establishment of the culture conditions required for in vitro induction of anti-p53 CTL, we intend to evaluate the generation of anti-p53 CTL from PBL obtained from the OSCC patients, prior to and following participation in clinical trials of p53 gene therapy and IL-12 protein and gene immunotherapy. An inherent part of this research will be to correlate these cellular studies with the anti-p53 humoral responses of these patients.

Project Start
1999-09-01
Project End
2000-08-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Whiteside, Theresa L; Ferris, Robert L; Szczepanski, Miroslaw et al. (2016) Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. Head Neck 38 Suppl 1:E494-501
Visus, Carmen; Ito, Diasuke; Dhir, Rajiv et al. (2011) Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas. Cancer Immunol Immunother 60:919-29
Hoffmann, Thomas K; Trellakis, Sokratis; Okulicz, Kornelia et al. (2011) Cyclin B1 expression and p53 status in squamous cell carcinomas of the head and neck. Anticancer Res 31:3151-7
Visus, Carmen; Wang, Yangyang; Lozano-Leon, Antonio et al. (2011) Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8? T cells. Clin Cancer Res 17:6174-84
Czystowska, Malgorzata; Strauss, Laura; Bergmann, Christoph et al. (2010) Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med (Berl) 88:577-88
Macatangay, Bernard J C; Szajnik, Marta E; Whiteside, Theresa L et al. (2010) Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One 5:e9852
Mandapathil, Magis; Hilldorfer, Benedict; Szczepanski, Miroslaw J et al. (2010) Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 285:7176-86
Andrade Filho, Pedro A; Ito, Daisuke; Deleo, Albert B et al. (2010) CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 59:1561-8
Albers, Andreas E; Schaefer, Carsten; Visus, Carmen et al. (2009) Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer. Head Neck 31:773-81
Chikamatsu, Kazuaki; Sakakura, Koichi; Takahashi, Goro et al. (2009) CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer. Cancer Immunol Immunother 58:1441-8

Showing the most recent 10 out of 94 publications